Primary Signet Ring Cell Mucinous Ovarian Carcinoma: A Case Report and Literature Review by El-Safadi, Samer et al.
 
Case Rep Oncol 2010;3:451–457 
DOI: 10.1159/000323003 
Published online: 
December 4, 2010 
© 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only. 
 
Dr. med. Samer El-Safadi    Department of Gynaecology and Obstetrics 
University Hospital Giessen and Marburg GmbH, Klinikstrasse 32 
DE–35392 Giessen (Germany) 
Tel. +49 641 99 45200, Fax + 49 641 99 45139 
E-Mail samer.el-safadi @ gyn.med.uni-giessen.de 
 
451
   
Primary Signet Ring Cell 
Mucinous Ovarian Carcinoma:  
A Case Report and Literature 
Review 
Samer El-Safadia    Ulrich Stahlb    Hans Rudolf Tinneberga    
Andreas Hackethala    Karsten Muenstedta  
aDepartment of Gynaecology and Obstetrics, University Hospital Giessen  
and Marburg GmbH, Giessen, and bInstitute of Pathology and Cytology,  
Wetzlar, Germany 
 
Key Words 
Krukenberg’s tumour · Mucinous carcinoma · Ovarian cancer · Pseudomyxoma peritonei · 
Signet ring cell carcinoma · Pulmonary complication 
 
Abstract 
A 24-year-old female patient presented with an extremely rare primary signet cell 
carcinoma of the right ovary 1 year after surgery for a mucinous borderline tumour of the 
left ovary. Relaparotomy was carried out with right adnexectomy, appendectomy and 
partial omentectomy. Surgery was followed by 6 courses of paclitaxel/carboplatinum 
chemotherapy. After an initial response, the patient again developed increasing ascites. 
The patient was transferred to our hospital and a re-relaparotomy was carried out, 
completing the operation. After 3 courses of pegylated doxorubicin/trabectedin, the 
clinical course showed a positive response and a decline of the tumour marker CEA in 
peripheral blood. After 5 months, ascites developed in the retroperitoneum so that the 
chemotherapy had to be changed. In spite of a positive response with the new 
chemotherapy, the patient died of a very rare pulmonary complication after 1 month 
within 2 days. 
 
Introduction 
Krukenberg was the first to describe a signet ring cell carcinoma of the ovary [1]. Later 
on it was shown that these carcinomas were metastases from tumours of the 
gastrointestinal tract [2, 3]. In the past few years, there were reports of 13 cases of primary 
ovarian stromal tumours with signet ring cells. Most of these were benign but 3 cases were 
primary mucinous signet ring cell carcinomas of the ovary [4, 5].  
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Case Report 
In August 2008, a 24-year-old nulligravida presented with a cystic mass of the left ovary measuring 
25 cm in diameter. Laparotomy was performed with removal of the ovary. During surgery, the cyst 
ruptured and histology revealed a mucinous borderline tumour of the ovary. The patient received no 
further treatment. 
One year later the patient presented again with ascites. Cytology after puncture showed malignant 
cells. A relaparotomy was carried out with right adnexectomy, appendectomy and partial omentectomy. 
The histologic examination of the right ovary showed a mucinous signet ring cell carcinoma of the 
ovary with peritoneal metastasis with a FIGO stage of IIIC (fig. 1). The tumour mass was widely spread 
in all areas of the peritoneum with a high infiltration of the bladder, colorectum and peritoneal serosa 
with pseudomyxoma peritonei. Because of the signet cell differentiation of the tumour, gastroscopy and 
CT scans were carried out which revealed no signs of gastrointestinal tumours. A complete histological 
examination of the appendix showed no primary carcinoma. Surgery was followed by 6 courses of 
paclitaxel/carboplatinum combination chemotherapy. After an initial response, the patient again 
developed increasing ascites. 
In December 2009, the patient was transferred to our hospital. She and her family strongly decided 
against a standard palliative approach with pegylated doxorubicin or topotecan. It was decided to 
complete surgery with a hysterectomy, omentectomy, extensive reduction of tumour masses, 
deperitonealisation of the small pelvis as well as pelvic and paraaortal lymphonodectomy. No 
macroscopic residual tumour was left in the abdominal cavity. There were no signs of distant 
metastases. During surgery the patient received hyperthermic intraperitoneal chemotherapy with 
mitomycin (HIPEC).  
Histological examination confirmed a signet cell adenocarcinoma of the ovary with extensive 
peritoneal carcinosis (fig. 2). The pTNM classification was pT3c G3 pN1 (1/20) L1 V0 R1. One lymph 
node in the fossa obturatoria was positive for metastasis. Immunohistochemical analyses showed no 
expression of the oestrogen receptor, progesterone receptor or HER2/neu receptors. Sequence analysis 
of EGFR showed wild type. However, the K-ras gene showed a codon 13 mutation (GGCĺGAC). 
The postoperative condition was complicated by a colon perforation. A lesion of the terminal ileum 
was sutured during emergency laparotomy. The patient recovered with a wide spectrum of antibiotics. 
The persistent thrombocytopenia (26,000/l) and the elevated liver enzymes (GOT 101 U/l, GPT 111 U/l, 
GGT 461 U/l) were probably the result of the hyperthermic intraperitoneal chemotherapy. Gradually, all 
values returned to normal. 
Drug sensitivity testing of the tumour cells showed sensitivity to pegylated doxorubicin, paclitaxel 
and capecitabine. After a thorough histological examination with comparisons to the initial mucinous 
borderline tumour of the left ovary, the signet cell carcinoma of the right ovary and the histology of the 
third laparotomy, it was decided to advise the patient to undergo 6 courses of pegylated doxorubicin in 
combination with trabectedin every 3 weeks. After 3 courses of treatment, the serum levels of the 
tumour marker CEA dropped from 966 to 207 ng/ml. The serum CA 12-5 level was 43.1 U/ml. After 
this extensive operation and with the above mentioned chemotherapy, the patient reached a high quality 
of life enabling her to pursue her hobbies and normal activities of life. 
Five months later, the patient presented again with nausea, vomiting, loss of weight and considerable 
ascites in the retroperitoneum. The tumour marker CEA was beyond 500 ng/ml. Cytology after CT-
controlled puncture showed malignant cells of the known ovarian cancer with low proliferation. The 
chemotherapy was changed to 3 courses of treosulfan every third week, bevacizumab every second 
week, Zoladex every fourth week and Zometa every third month. The CT scan after 1 month showed no 
ascites. The patient felt fine again and reached again a high quality of life, being able to pursue normal 
activities. After 1 month the patient died of pneumonitis, pulmonary hemorrhage and severe 
hemoptysis within 2 days.  
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Discussion 
This case report describes a very rare, poorly differentiated mucinous adenocarcinoma 
with signet ring cell differentiation and massive pseudomyxoma peritonei. It is not clear 
whether this signet cell carcinoma originated from the right ovary or whether cells from 
the mucinous borderline tumour, which spilled into the abdominal cavity at the first 
surgical intervention, caused this tumour.  
Signet Cell Carcinomas of the Ovary 
In general, primary signet cell carcinomas of the ovary are extremely rare. After the 
first description of a signet ring cell stromal tumour of the ovary [4], 15 other cases of 
primary signet cell tumours originating from the ovary were described; however, 13 of 
these cases were found to be benign according to the lack of mitotic activity and 
pleomorphism [4, 6–13]. Only 3 cases could be identified in the international literature on 
primary signet ring cell ovarian carcinoma. One of the reported tumours was a mucinous 
cystadenoma with a focal development of signet ring cell carcinoma. The other 2 tumours 
were mucinous adenofibromatous tumours with a focal signet ring cell carcinoma [5]. 
Signet ring cell mucinous carcinomas of the ovary are mostly metastases of primary 
tumours from the gastrointestinal tract, such as the stomach, the pancreas, the biliary 
tract or the appendix, or colorectal tumours. Primary tumours of the renal pelvis, urinary 
bladder, uterine cervix/corpus or mammary tumours with signet ring cell differentiation 
are very rare. Thus, the finding of a signet ring cell carcinoma in an ovary can no longer 
be classified as a metastatic tumour. On the contrary, it is necessary to distinguish the 
‘real’ Krukenberg tumour, a signet ring cell carcinoma of the ovary, from secondary 
malignancies by thorough examination of the gastrointestinal organs, excluding the 
occurrence of other primary tumours [5]. This approach is necessary to ensure proper 
treatment of these tumours, including surgery and consecutive chemotherapy. 
According to the literature, typical features of a primary rather than a metastatic 
tumour are unilateral localisation, low stage, background of adenofibroma or 
cystadenoma and sometimes an association with endometriosis. Moreover, there should 
be no evidence of metastatic tumour like bilateral tumour, deposits on the surface, 
nodular growth in microscopic and macroscopic examinations, extensive lymphovascular 
permeation, destructive stromal invasion, or tumour cells floating in mucin or 
extraovarian spread, although none of these would exclude this diagnosis [5, 9]. 
Histopathology of Signet Ring Cell Ovarian Cancer 
Histologically, the signet ring cells are characterized by middle-sized, vacuolated 
tumour cells with atypical nuclei, mitotic activity and PAS-positive intracytoplasmic 
vacuoles. The benign stromal tumour of the ovary has different characteristics compared 
to mucinous ovarian cancer (table 1). 
In our patient, a primary signet ring cell carcinoma of the right ovary developed after a 
mucinous cystic borderline tumour of the left ovary had been removed. The latter 
presented no similarity to the now extensive peritoneal metastasic tumour. In conclusion,  
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it can be assumed that a minute amount of poorly differentiated clones of malignant cells 
were contained in the primary borderline tumour, which was not detected in the first 
sampling. A primary appendix carcinoma was excluded. 
Most of the specific characteristics of a ‘real’ Krukenberg tumour were found in the 
presented case, such as lymphovascular invasion, nuclear atypia, signet ring cells, mitotic 
activity, surface tumour deposits, poor differentiation, high CEA level, pseudomyxoma 
peritonei, expression of enteric markers like CK7, but lack of CK20 and CDX-2 
expression which exclude colorectal or appendix tumours as the primary tumour. The 
description of a primary Krukenberg tumour or a second type of Krukenberg tumour has 
amply been discussed in the literature [5, 14]. 
Little is known about the prognosis of the primary ovarian mucinous tumour with 
signet ring cells. In stage IA, the prognosis seems to be favourable and similar to that of 
ovarian mucinous carcinoma without signet ring cells. An adverse impact on the 
prognosis can be expected by a massive overgrowth of signet ring cells [5]. 
Che et al. [15] published a follow-up of 31- to 78-year-old patients with primary 
microcystic ovarian carcinoma with signet ring cells. Most of them presented at FIGO 
stage III. Within 23 to 90 months after the initial diagnosis, 2 patients were without 
symptoms, 3 patients had other diseases and 4 patients died of recurrent or persistent 
disease. 
Treatment of Signet Ring Cell Carcinoma 
After an initial response to treatment the signet ring cell carcinoma showed no further 
response to the paclitaxel/carboplatinum standard treatment and rapidly progressed. Our 
treatment approach was not standard, but there was a rationale to it: hyperthermic 
intraperitoneal chemotherapy (HIPEC) with mitomycin after optimal cytoreduction (R0-
R1) has been proven to improve overall survival and disease-free survival in patients with 
recurrent ovarian cancer [16]. Another investigation of 52 patients with recurrent 
pseudomyxoma peritonei due to mucinous tumours (mucinous borderline tumour, 
tumour of the appendix) with a follow-up of 8.2 years showed 4 patients with no evidence 
of disease and the remaining cases with recurrences [17]. 
The choice of pegylated doxorubicin is in agreement with the most recent data from a 
trial consisting of 672 patients with recurrent platinum-sensitive ovarian cancer [18]. The 
selection of tumour therapy based on chemosensitivity assays has also been shown to be 
superior to those selected by physician’s choice [19]. We chose to combine pegylated 
doxorubicin with trabectedin after it was shown that this combination is superior to 
pegylated doxorubicin monotherapy [20]. 
After 5 months the patient presented again with increased ascites in the 
retroperitoneum. We chose the therapeutic approach as described above (fig. 3), since it 
showed no distinct side effects and a good quality of life [21]. 
The patient died after 1 month of a very rare complication of bevacizumab with 
hemoptysis, pneumonitis and pulmonary hemorrhage within 2 days. Deaths have been 
reported in 1.6% of patients treated with bevacizumab. Higher risk of deep venous 
thrombosis and pulmonary embolism in up to 31% of the cases has been reported [22].  
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Our experience with the very rare primary malignant signet ring cell carcinoma of the 
ovary should encourage the exploration of alternative treatments of this tumour and 
stimulate further research. The rare complications caused by bevacizumab should be kept 
in mind. 
 
 
Table 1. Characteristics of benign signet ring cell ovarian tumour versus malignant signet ring cell 
ovarian cancer [4, 8, 11, 12, 15, 23–26] 
Benign Malignant 
Nonmucin- and nonlipid-producing 
Cytoplasmic pseudoinclusions 
Endomatous extracellular matrix 
No hormone effects 
No obvious ascites 
Fibromatous backround 
 Infiltrating  pattern 
Nests of tumour cells  
Positivity of mucin (PAS positive) and cytokeratin  
Malignant-looking nuclei 
Sometimes dirty necrosis (nuclear debris) 
Sometimes associated with dermoid cyst or arising in 
dermoid cyst or part of teratoma 
Can be associated with low grade adenocarcinoma 
Poorly differentiated mucinous carcinoids of the ovary 
(neuroendocrine marker-positive) 
Can be associated with surface epithelial (serous, 
endometroid and mixed type) ovarian cancer 
 
 
 
 
 
Fig. 1. Signet ring cell carcinoma of the ovary. Tumour cells are indicated by an arrow. HE stain. 
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Fig. 2. Peritoneal carcinosis of a primary signet ring cell carcinoma. Peritoneal surface is indicated by 
arrows. HE stain. 
 
 
 
Fig. 3. Time axis of therapy procedure. 
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